- 期刊
- OpenAccess
Dual Antiplatelet Therapy in the Management of Acute Minor Ischemic Stroke and High-Risk Transient Ischemic Attack: An Expert Consensus Statement From Taiwan Stroke Society and Taiwan Society of Emergency Medicine
摘要
The aim of this review is to achieve a consensus between Taiwan Stroke Society (TSS) and Taiwan Society of Emergency Medicine (TSEM) to manage acute non-cardioembolic minor ischemic stroke (MIS) and high-risk transient ischemic attack (TIA). The methodology is to review the recent findings from clinical trials of dual antiplatelet therapy (DAPT) from 2010 to 2021 and updates in clinical practice guidelines from 2018 to 2022 for non-cardioembolic MIS/TIA management at the acute stage. Four leading clinical studies, CHANCE, POINT, THALES, and CHANCE-2 along with other relevant studies introducing DAPT, are discussed in this review. The risk-benefit profile between stroke recurrence reduction and major bleeding increase is also elucidated. TSS and TSEM concluded that for patients presenting with non-cardioembolic MIS or high-risk TIA who did not receive intravenous alteplase, initiation of DAPT within 24 hours after stroke onset and continued up to 21 days, followed by antiplatelet monotherapy, is effective in reducing recurrent ischemic stroke for a period of up to 90 days.
延伸閱讀
- 張雅婷（2007）。Cost-Effectiveness Analysis of Antiplatelet Therapy in the Prevention of Recurrent Stroke in Taiwan〔碩士論文，臺北醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0007-2701200815295200
- Lee, W. L., Wang, Y. C., Su, C. S., Lee, H. F., Tung, Y. C., Liu, P. Y., Su, C. H., Kuo, F. Y., Lin, W. S., Chu, P. H., Lu, T. M., Lo, P. H., Tsukiyama, S., Yang, W. C., Cheng, L. C., Yin, W. H., & Lin, Y. H. (2022). A HANC Risk Stratification Score for Antiplatelet Therapy Optimization with Low-Dose Prasugrel in Taiwanese Acute Coronary Syndrome Patients from the Switch Study. Acta Cardiologica Sinica, 38(6), 751-764. https://doi.org/10.6515/ACS.202211_38(6).20220702A
- Li, Y. H., Fang, C. Y., Hsieh, I. C., Huang, W. C., Lin, T. H., Sung, S. H., Chiu, C. Z., Wu, C. J., Shyu, K. G., Chang, P. Y., Fang, C. C., Lu, T. M., Chen, C. P., Tai, W. C., Sheu, C. C., Wei, K. C., Huang, Y. H., Wu, H. M., & Hwang, J. J. (2018). 2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan. Acta Cardiologica Sinica, 34(3), 201-210. https://doi.org/10.6515/ACS.201805_34(3).20180302A
- 湯頌君、鍾芷萍、陳柏霖、李孟、宋碧姍、劉崇祥、陳右緯、林雅如、連立明、張谷州、李俊泰、鄭建興、非心因性缺血性腦中風抗血小板藥物治療指引共識小組（2022）。2022 Focus Update of the 2020 Taiwan Stroke Society Guideline on Antiplatelet Therapy for Noncardioembolic Acute Ischemic Stroke。台灣中風醫誌，4(2)，53-60。https://doi.org/10.6318/FJS.202206_4(2).0001
- 江俊宜、賴昱樺、熊光華、黃建華、彭家勛、陳建生、陳穎信（2010）。A Comprehensive Thrombolysis Service for Patients with Acute Ischemic Stroke Administered Prehospital and in an Emergency Department in Northern Taiwan: A Pilot Study。台灣急診專科醫師期刊，2(3)，74-82。https://doi.org/10.29749/JTCEP.201009.0002